A citation-based method for searching scientific literature

Florian Rosar, Felix Wenner, Fadi Khreish, Sebastian Dewes, Gudrun Wagenpfeil, Manuela A Hoffmann, Mathias Schreckenberger, Mark Bartholomä, Samer Ezziddin. Eur J Nucl Med Mol Imaging 2022
Times Cited: 5







List of co-cited articles
20 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Oliver Sartor, Johann de Bono, Kim N Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T Tagawa, Luke T Nordquist, Nitin Vaishampayan, Ghassan El-Haddad,[...]. N Engl J Med 2021
352
60

89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man.
Bastiaan M Privé, Yvonne H W Derks, Florian Rosar, Gerben M Franssen, Steffie M B Peters, Fadi Khreish, Mark Bartholomä, Stephan Maus, Martin Gotthardt, Peter Laverman,[...]. Eur J Nucl Med Mol Imaging 2022
6
60

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Michael S Hofman, John Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G Murphy,[...]. Lancet Oncol 2018
577
60

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Michael S Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M Joshua, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Siobhan Ng,[...]. Lancet 2021
246
60

Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.
Bernhard Grubmüller, Daniela Senn, Gero Kramer, Pascal Baltzer, David D'Andrea, Karl Hermann Grubmüller, Markus Mitterhauser, Harald Eidherr, Alexander R Haug, Wolfgang Wadsak,[...]. Eur J Nucl Med Mol Imaging 2019
72
40

68Ga-PSMA I&T PET/CT for primary staging of prostate cancer.
Wojciech Cytawa, Anna Katharina Seitz, Stefan Kircher, Kazuhito Fukushima, Johannes Tran-Gia, Andreas Schirbel, Tomasz Bandurski, Piotr Lass, Markus Krebs, Wojciech Połom,[...]. Eur J Nucl Med Mol Imaging 2020
38
40

Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.
Matthias M Heck, Robert Tauber, Sebastian Schwaiger, Margitta Retz, Calogero D'Alessandria, Tobias Maurer, Andrei Gafita, Hans-Jürgen Wester, Jürgen E Gschwend, Wolfgang A Weber,[...]. Eur Urol 2019
130
40

Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177Lu-PSMA-617 Radioligand Therapy.
Robert Seifert, Konstantin Seitzer, Ken Herrmann, Katharina Kessel, Michael Schäfers, Jens Kleesiek, Matthias Weckesser, Martin Boegemann, Kambiz Rahbar. Theranostics 2020
44
40


Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.
Magdalena Staniszewska, Pedro Fragoso Costa, Matthias Eiber, Jasmin M Klose, Jasmin Wosniack, Henning Reis, Tibor Szarvas, Boris Hadaschik, Katharina Lückerath, Ken Herrmann,[...]. Int J Mol Sci 2021
9
40

Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases?
Conrad Leitsmann, Paul Thelen, Marianne Schmid, Johannes Meller, Carsten-Oliver Sahlmann, Birgit Meller, Lutz Trojan, Arne Strauss. Int Braz J Urol 2019
13
40

177Lu-PSMA Radioligand Therapy for Prostate Cancer.
Wolfgang P Fendler, Kambiz Rahbar, Ken Herrmann, Clemens Kratochwil, Matthias Eiber. J Nucl Med 2017
99
40


Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients.
Sofia Vaz, Boris Hadaschik, Michael Gabriel, Ken Herrmann, Matthias Eiber, Durval Costa. Eur J Nucl Med Mol Imaging 2020
40
40

PSMA Ligands for PET Imaging of Prostate Cancer.
Sarah M Schwarzenboeck, Isabel Rauscher, Christina Bluemel, Wolfgang P Fendler, Steven P Rowe, Martin G Pomper, Ali Afshar-Oromieh, Ken Herrmann, Matthias Eiber. J Nucl Med 2017
120
40

68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.
Wolfgang P Fendler, Matthias Eiber, Mohsen Beheshti, Jamshed Bomanji, Francesco Ceci, Steven Cho, Frederik Giesel, Uwe Haberkorn, Thomas A Hope, Klaus Kopka,[...]. Eur J Nucl Med Mol Imaging 2017
398
40


Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade.
Louise Emmett, Charlotte Yin, Megan Crumbaker, George Hruby, Andrew Kneebone, Richard Epstein, Quoc Nguyen, Adam Hickey, Noah Ihsheish, Gordon O'Neill,[...]. J Nucl Med 2019
85
40

Prostate-specific membrane antigen expression in normal and malignant human tissues.
D A Silver, I Pellicer, W R Fair, W D Heston, C Cordon-Cardo. Clin Cancer Res 1997
40

F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.
Frederik L Giesel, B Hadaschik, J Cardinale, J Radtke, M Vinsensia, W Lehnert, C Kesch, Y Tolstov, S Singer, N Grabe,[...]. Eur J Nucl Med Mol Imaging 2017
291
40

68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Christian Schmidkonz, Michael Cordes, Theresa Ida Goetz, Olaf Prante, Torsten Kuwert, Philipp Ritt, Michael Uder, Bernd Wullich, Peter Goebell, Tobias Bäuerle. Ann Nucl Med 2019
20
20

Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience.
Berna Okudan, Nazim Coşkun, Bedri Seven, Merve Ağcioğlu Atalay, Aslihan Yildirim, Fatma Arzu Görtan. Nucl Med Commun 2021
4
25


The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study.
Hojjat Ahmadzadehfar, Ralf Matern, Richard P Baum, Robert Seifert, Katharina Kessel, Martin Bögemann, Clemens Kratochwil, Hendrik Rathke, Harun Ilhan, Hanna Svirydenka,[...]. Eur J Nucl Med Mol Imaging 2021
8
20

68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.
Alexander Heinzel, Dima Boghos, Felix M Mottaghy, Florian Gaertner, Markus Essler, Dirk von Mallek, Hojjat Ahmadzadehfar. Eur J Nucl Med Mol Imaging 2019
33
20

68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer.
Christian Schmidkonz, Michael Cordes, Daniela Schmidt, Tobias Bäuerle, Theresa Ida Goetz, Michael Beck, Olaf Prante, Alexander Cavallaro, Michael Uder, Bernd Wullich,[...]. Eur J Nucl Med Mol Imaging 2018
64
20


The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival.
Emine Acar, Özhan Özdoğan, Ayşegül Aksu, Erkan Derebek, Recep Bekiş, Gamze Çapa Kaya. Ann Nucl Med 2019
14
20

Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer.
Sebastian Schmuck, Christoph A von Klot, Christoph Henkenberens, Jan M Sohns, Hans Christiansen, Hans-Jürgen Wester, Tobias L Ross, Frank M Bengel, Thorsten Derlin. J Nucl Med 2017
92
20

Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction.
Zain Khurshid, Hojjat Ahmadzadehfar, Florian C Gaertner, László Papp, Norbert Zsóter, Markus Essler, Ralph A Bundschuh. Oncotarget 2018
20
20

Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.
Louise Emmett, Kathy Willowson, John Violet, Jane Shin, Ashley Blanksby, Jonathan Lee. J Med Radiat Sci 2017
135
20

LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity.
Christophe Nioche, Fanny Orlhac, Sarah Boughdad, Sylvain Reuzé, Jessica Goya-Outi, Charlotte Robert, Claire Pellot-Barakat, Michael Soussan, Frédérique Frouin, Irène Buvat. Cancer Res 2018
413
20

Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.
Sven Perner, Matthias D Hofer, Robert Kim, Rajal B Shah, Haojie Li, Peter Möller, Richard E Hautmann, Juergen E Gschwend, Rainer Kuefer, Mark A Rubin. Hum Pathol 2007
305
20

Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial).
Hojjat Ahmadzadehfar, Kambiz Rahbar, Richard P Baum, Robert Seifert, Katharina Kessel, Martin Bögemann, Harshad R Kulkarni, Jingjing Zhang, Carolin Gerke, Rolf Fimmers,[...]. Eur J Nucl Med Mol Imaging 2021
42
20

Results of a Prospective Phase 2 Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression.
Louise Emmett, Megan Crumbaker, Bao Ho, Kathy Willowson, Peter Eu, Lalith Ratnayake, Richard Epstein, Ashley Blanksby, Lisa Horvath, Alex Guminski,[...]. Clin Genitourin Cancer 2019
98
20

Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.
Philip A Watson, Vivek K Arora, Charles L Sawyers. Nat Rev Cancer 2015
733
20

New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide.
Florian Rosar, Sebastian Dewes, Martin Ries, Andrea Schaefer, Fadi Khreish, Stephan Maus, Hendrik Bohnenberger, Johannes Linxweiler, Mark Bartholomä, Carsten Ohlmann,[...]. Eur J Nucl Med Mol Imaging 2020
26
20

Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
Rahul Aggarwal, Xiao Wei, Won Kim, Eric J Small, Charles J Ryan, Peter Carroll, Matthew Cooperberg, Michael J Evans, Thomas Hope. Eur Urol Oncol 2018
46
20

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Johann Sebastian de Bono, Stephane Oudard, Mustafa Ozguroglu, Steinbjørn Hansen, Jean-Pascal Machiels, Ivo Kocak, Gwenaëlle Gravis, Istvan Bodrogi, Mary J Mackenzie, Liji Shen,[...]. Lancet 2010
20

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
20

Abiraterone and increased survival in metastatic prostate cancer.
Johann S de Bono, Christopher J Logothetis, Arturo Molina, Karim Fizazi, Scott North, Luis Chu, Kim N Chi, Robert J Jones, Oscar B Goodman, Fred Saad,[...]. N Engl J Med 2011
20

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
725
20

Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.
Katharina Lückerath, Liu Wei, Wolfgang P Fendler, Susan Evans-Axelsson, Andreea D Stuparu, Roger Slavik, Christine E Mona, Jeremie Calais, Matthew Rettig, Robert E Reiter,[...]. EJNMMI Res 2018
41
20

Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.
Jose D Murga, Sameer M Moorji, Amy Q Han, Wells W Magargal, Vincent A DiPippo, William C Olson. Prostate 2015
55
20

German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
Kambiz Rahbar, Hojjat Ahmadzadehfar, Clemens Kratochwil, Uwe Haberkorn, Michael Schäfers, Markus Essler, Richard P Baum, Harshad R Kulkarni, Matthias Schmidt, Alexander Drzezga,[...]. J Nucl Med 2017
468
20

Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges.
Martin K Bakht, So Won Oh, Hyewon Youn, Gi Jeong Cheon, Cheol Kwak, Keon Wook Kang. Nucl Med Mol Imaging 2017
32
20

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617.
Justin Ferdinandus, John Violet, Shahneen Sandhu, Rodney J Hicks, Aravind S Ravi Kumar, Amir Iravani, Grace Kong, Tim Akhurst, Sue Ping Thang, Declan G Murphy,[...]. Eur J Nucl Med Mol Imaging 2020
59
20



Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells.
Benedikt Kranzbühler, Souzan Salemi, Christoph A Umbricht, Cristina Müller, Irene A Burger, Tullio Sulser, Daniel Eberli. Prostate 2018
36
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.